vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and REED'S, INC. (REED). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.5M, roughly 1.2× REED'S, INC.). REED'S, INC. runs the higher net margin — -50.5% vs -60.3%, a 9.8% gap on every dollar of revenue. On growth, REED'S, INC. posted the faster year-over-year revenue change (-23.1% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-3.9M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -11.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Waddell & Reed Financial, Inc. was an American asset management and financial planning company founded in 1937 in Kansas City, Missouri. It was a publicly traded company from 1998 to 2021, and briefly had its headquarters in Overland Park, Kansas, and was planning a move back to Downtown Kansas City before the company was sold. It operated asset management and distribution subsidiaries, including Ivy Investment Management Company and Waddell & Reed Investment Management Company.
PLX vs REED — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $7.5M |
| Net Profit | $-5.5M | $-3.8M |
| Gross Margin | 49.4% | 20.4% |
| Operating Margin | -51.1% | -46.9% |
| Net Margin | -60.3% | -50.5% |
| Revenue YoY | -49.9% | -23.1% |
| Net Profit YoY | -184.8% | 8.2% |
| EPS (diluted) | $-0.06 | $-1.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $7.5M | ||
| Q3 25 | $17.9M | $7.0M | ||
| Q2 25 | $15.7M | $9.5M | ||
| Q1 25 | $10.1M | $10.0M | ||
| Q4 24 | $18.2M | $9.7M | ||
| Q3 24 | $18.0M | $6.8M | ||
| Q2 24 | $13.5M | $11.9M | ||
| Q1 24 | — | $9.6M |
| Q4 25 | $-5.5M | $-3.8M | ||
| Q3 25 | $2.4M | $-4.0M | ||
| Q2 25 | $164.0K | $-6.0M | ||
| Q1 25 | $-3.6M | $-2.0M | ||
| Q4 24 | $6.5M | $-4.1M | ||
| Q3 24 | $3.2M | $-4.2M | ||
| Q2 24 | $-2.2M | $-3.2M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | 49.4% | 20.4% | ||
| Q3 25 | 53.4% | 17.4% | ||
| Q2 25 | 62.5% | 8.5% | ||
| Q1 25 | 19.1% | 33.9% | ||
| Q4 24 | 78.7% | 30.0% | ||
| Q3 24 | 53.4% | 18.0% | ||
| Q2 24 | 29.8% | 32.3% | ||
| Q1 24 | — | 35.6% |
| Q4 25 | -51.1% | -46.9% | ||
| Q3 25 | 11.9% | -58.3% | ||
| Q2 25 | 7.5% | -60.8% | ||
| Q1 25 | -41.0% | -17.4% | ||
| Q4 24 | 39.6% | -37.6% | ||
| Q3 24 | 22.2% | -46.5% | ||
| Q2 24 | -18.0% | -5.6% | ||
| Q1 24 | — | -6.8% |
| Q4 25 | -60.3% | -50.5% | ||
| Q3 25 | 13.2% | -56.6% | ||
| Q2 25 | 1.0% | -63.5% | ||
| Q1 25 | -35.8% | -20.3% | ||
| Q4 24 | 35.6% | -42.3% | ||
| Q3 24 | 18.0% | -61.5% | ||
| Q2 24 | -16.4% | -27.1% | ||
| Q1 24 | — | -17.4% |
| Q4 25 | $-0.06 | $-1.26 | ||
| Q3 25 | $0.03 | $-0.48 | ||
| Q2 25 | $0.00 | $-0.13 | ||
| Q1 25 | $-0.05 | $-0.04 | ||
| Q4 24 | $0.10 | $-3.73 | ||
| Q3 24 | $0.03 | $-4.91 | ||
| Q2 24 | $-0.03 | $-0.77 | ||
| Q1 24 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $9.2M |
| Total Assets | $82.3M | $23.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $48.2M | $9.2M | ||
| Q3 25 | $52.9M | $2.8M | ||
| Q2 25 | $49.9M | $1.7M | ||
| Q1 25 | $45.2M | $4.7M | ||
| Q4 24 | $43.2M | $6.6M | ||
| Q3 24 | $32.4M | $-22.0M | ||
| Q2 24 | $28.6M | $-23.8M | ||
| Q1 24 | — | $-20.7M |
| Q4 25 | $82.3M | $23.3M | ||
| Q3 25 | $82.3M | $19.9M | ||
| Q2 25 | $78.5M | $23.7M | ||
| Q1 25 | $73.9M | $24.5M | ||
| Q4 24 | $73.4M | $25.1M | ||
| Q3 24 | $61.6M | $15.0M | ||
| Q2 24 | $91.5M | $18.7M | ||
| Q1 24 | — | $19.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-3.8M |
| Free Cash FlowOCF − Capex | $1.6M | $-3.9M |
| FCF MarginFCF / Revenue | 17.8% | -52.0% |
| Capex IntensityCapex / Revenue | 4.4% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-17.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-3.8M | ||
| Q3 25 | $-3.7M | $-2.8M | ||
| Q2 25 | $-5.2M | $-5.0M | ||
| Q1 25 | $-5.1M | $-5.4M | ||
| Q4 24 | $4.0M | $-3.9M | ||
| Q3 24 | $4.1M | $1.1M | ||
| Q2 24 | $-3.6M | $-912.0K | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | $1.6M | $-3.9M | ||
| Q3 25 | $-4.2M | $-2.9M | ||
| Q2 25 | $-5.7M | $-5.1M | ||
| Q1 25 | $-5.4M | $-5.4M | ||
| Q4 24 | $3.6M | $-4.0M | ||
| Q3 24 | $4.0M | $1.0M | ||
| Q2 24 | $-3.8M | $-924.0K | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | 17.8% | -52.0% | ||
| Q3 25 | -23.7% | -41.5% | ||
| Q2 25 | -36.2% | -53.2% | ||
| Q1 25 | -53.0% | -54.2% | ||
| Q4 24 | 19.6% | -40.8% | ||
| Q3 24 | 22.4% | 15.3% | ||
| Q2 24 | -28.1% | -7.8% | ||
| Q1 24 | — | -25.1% |
| Q4 25 | 4.4% | 1.1% | ||
| Q3 25 | 2.8% | 1.4% | ||
| Q2 25 | 2.8% | 0.2% | ||
| Q1 25 | 3.0% | 0.7% | ||
| Q4 24 | 2.3% | 1.0% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 1.3% | 0.1% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
REED
Segment breakdown not available.
